Delgocitinib

Delgocitinib functions primarily as a Janus kinase (JAK) inhibitor. JAKs are enzymes that play a crucial role in the signaling pathways involved in inflammation and immune responses. By inhibiting the JAK pathways, delgocitinib disrupts the signaling cascade that leads to the production of inflammatory cytokines.

The inhibition of JAKs by delgocitinib reduces the inflammatory response that characterizes conditions such as atopic dermatitis, chronic hand eczema, and other inflammatory skin disorders. This mechanism helps in alleviating symptoms like itching, redness, and swelling. The efficacy of delgocitinib in these conditions has been demonstrated in clinical studies, such as the Phase IIb trial assessing its use in atopic dermatitis (PMID: 42483929) and trials on chronic hand eczema (NCT03683719).

It is important to note that while JAK inhibition addresses inflammation, its impact on the entire immune system requires careful monitoring for side effects, as JAK inhibitors can potentially affect normal immune function.

Disclaimer: This information is intended for educational and informational purposes only and should not be used as a substitute for professional medical advice.

Clinical Applications of Delgocitinib

Delgocitinib is primarily used for treating dermatological conditions such as atopic dermatitis and chronic hand eczema. Its efficacy has been evaluated in several clinical trials and case reports:

1. Atopic Dermatitis: An 8-week randomized Phase IIb trial demonstrated a dose-dependent improvement in adults with mild to severe atopic dermatitis when using a cream formulation of delgocitinib. This study supports its potential as a therapeutic option for this condition (The British Journal of Dermatology, 2026).

2. Chronic Hand Eczema: Delgocitinib has been studied extensively for chronic hand eczema. A Phase 2b trial over 16 weeks assessed various dosages, showing positive outcomes in the management of moderate to severe cases (Expert Opinion on Pharmacotherapy, 2026). Additionally, real-world evidence supports its effectiveness and improvement in quality of life for patients with chronic hand eczema (Dermatitis, 2026).

3. Vulvar Lichen Sclerosus: In a case report, delgocitinib cream was used for refractory vulvar lichen sclerosus, suggesting it may be beneficial where other treatments have failed (JAAD Case Reports, 2026).

4. Frontal Fibrosing Alopecia: A completed Phase II trial evaluated its effects on the molecular signature and efficacy in adults with frontal fibrosing alopecia, though specific results from this study are not detailed in the provided evidence.

5. Pediatric Atopic Dermatitis: A systematic review focused on topical Janus Kinase inhibitors, including delgocitinib, highlighted potential benefits for pediatric atopic dermatitis, indicating an area under investigation (Pediatric Dermatology, 2026).

It is noteworthy that ongoing and completed trials are exploring additional uses and confirming the safety profile of delgocitinib in various dermatological conditions.

Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for medical care and treatment.

Safety Profile of Delgocitinib

Delgocitinib is generally used in a cream formulation for treating various dermatological conditions, including atopic dermatitis and chronic hand eczema. The safety profile described in the available studies is as follows:

Known Side Effects:

1. Skin Irritation: Some patients may experience irritation where the cream is applied.
2. Itching and Redness: Common reactions can include itching (pruritus) and redness at the site of application.
3. Burning Sensation: A transient burning sensation has been reported, which typically resolves on continued use.

Contraindications:

The current data do not provide explicit contraindications for delgocitinib. However, as with any topical medication, it should not be used by individuals with known hypersensitivity to its components.

Drug Interactions:

Based on the evidence, there are no specific studies detailing interactions between delgocitinib and other medications. This area requires further research for conclusive information.

Populations to Avoid Use:

1. Pregnant or Nursing Women: The safety of delgocitinib in pregnant or breastfeeding women has not been established.
2. Children: While a systematic review included pediatric subjects, no conclusive safety data specific to children were highlighted.
3. Patients with Severe Skin Conditions Beyond Study Scope: Those with skin conditions outside the ones studied, such as severe psoriasis, should use the cream under close medical supervision.

Additional Considerations:

• Chronic Hand Eczema Studies: Evidence from real-world and phase 2 trials suggests a favorable safety profile for chronic hand eczema, but further real-world data may help solidify understanding.
• UV-light Sensitivity: A phase 1 study evaluated allergic reactions related to UV exposure, indicating a need for caution regarding sunlight exposure after application.

In summary, while the existing data suggests a favorable safety profile for delgocitinib, the evidence is still evolving, especially concerning specific interactions and use in vulnerable populations. Patients should consult healthcare providers for personalized advice.

Disclaimer: This summary is for informational purposes and should not be used for diagnosing or treating health problems. Please consult a healthcare professional for personal medical advice.

Research Papers and Clinical Trials on Delgocitinib

Delgocitinib for Atopic Dermatitis:
A Phase IIb trial published in The British Journal of Dermatology examined the effects of Delgocitinib cream in adults with mild to severe atopic dermatitis. This 8-week randomized study demonstrated a dose-dependent response, indicating its efficacy across varying dosages (PMID: 42483929).

Treatment of Vulvar Lichen Sclerosus:
A case report in JAAD Case Reports highlighted Delgocitinib's potential in treating refractory vulvar lichen sclerosus, although specific details about the study size or outcomes weren’t detailed in the summary provided (PMID: 42436909).

Chronic Hand Eczema:
Multiple studies have assessed Delgocitinib for hand eczema. An article in Expert Opinion on Pharmacotherapy evaluated its use in moderate to severe cases, while a letter in Dermatitis reported improvements in quality of life for chronic hand eczema patients using this treatment (PMIDs: 42429252, 42318861).

A Phase 2b trial (NCT03683719) aimed to determine the optimal dosage over a 16-week period, evaluating doses ranging from 1 mg/g to 20 mg/g. This trial was completed, showing promising results across different concentrations.

A related real-world evidence study (NCT07603193) is enrolling by invitation, potentially adding further insights into the effectiveness and safety of Delgocitinib for hand eczema.

Miscellaneous Applications:
A systematic review in Pediatric Dermatology included topical Janus kinase inhibitors like Delgocitinib for pediatric atopic dermatitis, but specific findings were not detailed in the available evidence (PMID: 42289185).

Additionally, a Phase 2 clinical trial (NCT05332366) investigated Delgocitinib cream for frontal fibrosing alopecia, examining molecular signature and efficacy.

Safety and Efficacy:
A Phase 1 trial (NCT04807751) explored the safety of Delgocitinib when exposed to UV-light, assessing the potential for allergic skin reactions. This study's results may support understanding of its safety profile under diverse conditions.

Conclusion:
Delgocitinib shows promise across various dermatological conditions, with ongoing studies to further clarify its efficacy and safety. However, further real-world data and larger-scale trials could enhance understanding of its broader applications.

Disclaimer: This overview is informational and not a substitute for professional medical advice. Always consult a healthcare provider for personal health concerns.

Delgocitinib Dosing/Administration Protocols

Delgocitinib is commonly formulated as a topical cream for various dermatological conditions. The following protocols have been reported in the literature:

1. Atopic Dermatitis:

   • In a Phase IIb trial, adult patients with mild to severe atopic dermatitis showed a dose-dependent response to delgocitinib cream. The specific dosing regimen used in this trial, however, is not detailed in the provided evidence.

2. Chronic Hand Eczema:

   • Clinical trials, including NCT03683719, evaluated delgocitinib cream at dosages of 1, 3, 8, and 20 mg/g over a 16-week period. The details of specific application frequency (e.g., once or twice daily) are not provided in the available information.

3. Vulvar Lichen Sclerosus:

   • A case report describes the use of delgocitinib cream for refractory vulvar lichen sclerosus, but specific dosing details are not mentioned in the data reviewed.

Unfortunately, the exact application frequencies and comprehensive dosage instructions are not explicitly provided in the evidence available. For precise dosing information, direct guidance from healthcare professionals and official prescribing information should be sought.

Disclaimer: This information is intended for educational purposes and is not a substitute for professional medical advice. Always consult a healthcare provider for personal medical guidance.

Delgocitinib, a topical JAK inhibitor, has shown promising outcomes in various dermatological conditions. Below is a summary of reported outcomes:

1. Atopic Dermatitis: An 8-week randomized Phase IIb trial demonstrated that delgocitinib cream provided a dose-dependent reduction in symptoms for adults with mild to severe atopic dermatitis. The study indicates a robust response to treatment, suggesting efficacy in reducing the severity of dermatitis symptoms (PMID: 42483929).

2. Chronic Hand Eczema: Multiple studies have evaluated delgocitinib for hand eczema. In a Phase 2b dose-ranging trial, the cream was shown to effectively decrease eczema severity over a 16-week treatment period (NCT03683719). Another study reported improvement in quality of life measures in patients with chronic hand eczema (PMID: 42318861). These findings suggest meaningful clinical benefits, though ongoing studies aim to solidify understanding (e.g., NCT07603193).

3. Vulvar Lichen Sclerosus: In a case report, delgocitinib was found effective for treating refractory vulvar lichen sclerosus, indicating potential benefits in this condition (PMID: 42436909). However, evidence is limited to this single report, highlighting the need for further research.

4. Other Conditions: Additional investigations include exploring its effect on frontal fibrosing alopecia and potential UV-light-induced skin reactions. However, outcomes from these studies are less documented.

The evidence for delgocitinib's efficacy is strongest in atopic dermatitis and hand eczema, with moderate support for use in other conditions. Further research, particularly large-scale randomized controlled trials, is needed to confirm these findings and better understand its applications.

Disclaimer: This summary is for informational purposes only and should not be considered medical advice. For personal medical concerns, consult a healthcare professional.